P < 0.05) among fully vaccinated children (n = 101) when compared to unvaccinated children (n = 141). Secondly, there was no significant reduction in ILI and visits to physician among partially vaccinated children (n = 52) versus unvaccinated children (OR: 1.54 [0.77–3.07], P = 0.24 and OR: 1.81 [0.63–5.27], P = 0.30) respectively. CONCLUSIONS: Derived from these findings, it is concluded that seasonal influenza vaccine is effective in reducing the ILI and visits to physician for ARI among fully vaccinated Indian children. Partially vaccinated children had no statistically significant protection against ILI and visits to physician. To the best of our knowledge, this is the first report on the clinical effectiveness of seasonal influenza vaccine in healthy Indian children. 

**PIN9 Efficacy and Safety of Raltegravir in Treatment-naive HIV+ Patients: A Mixed Treatment Comparison Approach**

LeReun C1, Tilden D2, Harvey C3, Price B4, Van Bavel J1

1Independent Biostatistics, Carriag e county, Cork, Ireland; 2THEMA Consulting Ltd, Pymont, New South Wales, Australia; 3MSD Sydney, New South Wales, Australia

OBJECTIVES: To assess the efficacy and safety of raltegravir (integrase strand transfer inhibitor) compared to non-nucleoside reverse transcriptase inhibitors (nevirapine, efavirenz) and protease inhibitors (lopinavir, atazanavir) in treatment-naive patients with HIV infection. METHODS: A systematic literature search identified seven treatment-naive trials comparing raltegravir to other treatments in terms of health outcomes. The network of comparisons was analyzed using a Mixed Treatment Comparison (MTC) model. Selected outcomes were the proportion of patients with plasma HIV RNA levels less than 50 copies per mL and discontinuations (safety). A Bayesian approach was chosen and implemented in WinBUGS. Fixed-effect and random-effect models were run and the most appropriate model was selected based on the performance of the Monte Carlo simulations and the Deviance Information Criterion. Results were reported as median odds ratios, relative risk, and risk difference of raltegravir versus each comparator and associated 95% credible intervals. Bayesian inference also allows for treatment to be ranked, by calculating the proportion of simulations in which this treatment performs “best” in terms of relative efficacy/safety. RESULTS: For both efficacy and safety outcomes the fixed-effect models were preferred. Efficacy results showed a significant advantage of raltegravir compared to atazanavir, lopinavir, and nevirapine. Raltegravir also performed numerically better than efavirenz, and overall had a 7% probability of being the more efficacious treatment on this outcome. Safety results also favored Raltegravir, but significance was only reached compared to nevirapine. CONCLUSIONS: The MTC suggests that raltegravir has an advantage that is at least numerical and in some cases statistically significant over its comparators in terms of achieving plasma HIV less than 50 copies per mL and avoiding discontinuation, providing additional data that supports the use of raltegravir in this indication.

**PIN10 A Systematic Review of the Attribution of Human Papillomavirus Types Among Cervical Intraepithelial Neoplasia and Cervical Cancers in Japan by Sampling Methods**

Kimura T1

1Banyu (Merck), Tokyo, Japan

OBJECTIVES: Estimating vaccine effectiveness is crucial for policymakers. Human Papillomavirus (HPV) type-specific attribution to cervical cancers and precancers is a key factor in this regard for HPV vaccination and cancer screening. Among a number of factors, HPV type prevalence, a few investigated attributes of HPV, such as considering multiple infections and sampling methods. The objective of this study was to elucidate HPV type-specific attribution in Japanese women. METHODS: A systematic review of published studies was conducted. Sampling methods were divided into two categories: one group consists of studies where HPV DNA was extracted from exfoliated cells, and another group consists of those using tissue specimens obtained by biopsy or surgical resection. To elucidate interrelationships among multiple HPV types in contributing to lesion development, attribution of each HPV was estimated assuming a fractional allocation of multifactor infection. RESULTS: The overall positivity for any HPV was consistently higher in the exfoliated-cell group. On the other hand, attribution of HPV types 16 and 18 to cervical lesions was normally higher in the tissue-specimen group. Attribution of HPV types 16 and 18 to cervical squamous cell carcinoma (SCC) was estimated as 47.4% (95% CI: 43.8–51.1) and 9.4% (7.5–11.7) in the tissue-specimen group and 43.3% (38.4–48.2) and 7.6% (5.4–10.6) in the exfoliated-cell group, respectively. CONCLUSIONS: HPV positivity was higher in the exfoliated-cell group while type 16/18 attribution was normally higher in the tissue-specimen group. Attribution of HPV type 16 to SCCs and adenocarcinomas (AC) derived from tissue specimens, after adjustment for multiple-type infections, was >20% lower in Japanese women compared to data previously reported for US women. Type 18 attribution in Japanese women was similar to the United States for SCC and 10% lower for AC.

**INFECTION – Cost Studies**

**PIN11 COST ANALYSIS OF ADVERSE DRUG EVENTS GROM GPO-VIR®S AND GPO-VIR®Z IN PEOPLE LIVING WITH HIV/AIDS IN THAILAND**

Srimongkon P1, Supakul S2, Lucksi A3, Permsovan L4

1Maharakham University, Karthanauchai, Maharakham, Thailand; 2Chiang Mai University, Chiang Mai, Thailand

OBJECTIVES: GPO VIR® S (Stavudine, Lamivudine, Nevirapine) has been used in people living with HIV/AIDS in Thailand since 2002. Drug resistance and adverse drug events (ADEs) are likely to be found. To solve this problem, GPO VIR® Z (Zidovudine, Lamivudine, Nevirapine) has been developed since 2005. Therefore, this study was conducted to evaluate the costs of ADEs found in people living with HIV/AIDS receiving GPO-VIR® S compared with GPO-VIR® Z. METHODS: A retrospective cohort study design was used to determine the ADE costs of GPO-VIR® S and GPO-VIR® Z based on provider’s perspective. Direct medical costs (i.e., drug, laboratory, hospitalization, administration etc.) were directly collected from patient profiles from March 2005 to May 2008 at Nakorpon hospital, Chiangmai province, Thailand. Total cost and average cost per ADE were calculated. RESULTS: A total of 136 patients were studied. Of those, 95 cases received GPO-VIR® S and 41 cases received GPO-VIR® Z. Total ADEs found were 57 and 14 in GPO-VIR® S and GPO-VIR® Z groups respectively. Lipodystrophy (52.6%) was the most common ADE in GPO-VIR® S group and while anemia (28.7%) was found in GPO-VIR® Z group. The total cost was 929,971 baht and 65,394 baht in GPO-VIR® S and GPO-VIR® Z respectively. An average cost per event in GPO-VIR® S group was 16,210 baht and GPO-VIR® Z group was 4686 baht. CONCLUSIONS: Although treatment with GPO-VIR® Z seems to present lower costs of ADEs, selection of drug regimen still need to depend on the symptoms of individual patient.

**PIN12 COST-OF-ILLNESS OF CHRONIC HEPATITIS B INFECTION IN VIETNAM**

Ts H1, Riewpaiboon A2, Woordenberg H1, Postma M1, Le SC3

1University of Groningen, Groningen, The Netherlands; 2Mahidol University Faculty of Pharmacy, Bangkok, Thailand; 3University of Newcastle, Callaghan, NSW, Australia

OBJECTIVES: To quantify the financial burden of chronic hepatitis B (CHB) infection and its complications in a cost-of-illness study in Vietnam, a highly endemic country of hepatitis B virus (HBV) infection. METHODS: The study adopted the micro-costing approach. For direct medical cost estimation, data were retrieved retrospectively from medical histories of inpatients and outpatients with various CHB infection stages in 2008 from a large referral hospital in Vietnam. For direct nonmedical and indirect cost estimation, data were obtained from outpatients from the same hospital through face-to-face interviews. One- and two-way analyses were performed on the cost calculated. RESULTS: In 2008, the total cost of CHB infection and its complications was estimated to be around US$ 10 billion, with 80% contributable to direct medical cost. Antivirals were the major cost driver in treating CHB infections. The per-patient total annual direct medical cost increased with the severity of the disease with the cost amounted to US$ 943.64 for CHB and US$ 3916.21 for hepatocellular carcinoma. Based on the results, if all Vietnamese patients received treatment for CHB infections, the estimated cost would be twice as much as the total health budget of Vietnam, highlighting that a significant proportion of CHB infections in Vietnam are not being treated and the patients are bearing the extra cost out-of-pocket, or seeking treatment from traditional medicines. CONCLUSIONS: This study confirms that chronic HBV infection poses an unbearable financial burden for the average patient with a GDP per capita of around $1024, and the lack of access to treatment is a social issue in Vietnam. To reduce the number of infected subjects, more health-care investment to improve access and provision of affordable medications by re-examining pharmaceutical policies to attain equity in proper treatment for patients with CHB infections would be needed.

**PIN13 BURDEN AND MEDICAL COSTS OF ANOGENITAL WARTS IN BANGKOK, THAILAND**

Dhitavat J1, Charoenwatanachokchai A2, Kongsin S1, Kaewkungwal J1, Ruengkris T2, Bussaradt V1, Pirutsathit P1

1Mahidol University, Bangkok, Bangkok, Thailand; 2Ministry of Public Health, Bangkok, Bangkok, Thailand

OBJECTIVES: To quantify the financial burden of chronic hepatitis B (CHB) infection and its complications in a cost-of-illness study in Vietnam, a highly endemic country of hepatitis B virus (HBV) infection. METHODS: The study adopted the micro-costing approach. For direct medical cost estimation, data were retrieved retrospectively from medical histories of inpatients and outpatients with various CHB infection stages in 2008 from a large referral hospital in Vietnam. For direct nonmedical and indirect cost estimation, data were obtained from outpatients from the same hospital through face-to-face interviews. One- and two-way analyses were performed on the cost calculated. RESULTS: In 2008, the total cost of CHB infection and its complications was estimated to be around US$ 10 billion, with 80% contributable to direct medical cost. Antivirals were the major cost driver in treating CHB infections. The per-patient total annual direct medical cost increased with the severity of the disease with the cost amounted to US$ 943.64 for CHB and US$ 3916.21 for hepatocellular carcinoma. Based on the results, if all Vietnamese patients received treatment for CHB infections, the estimated cost would be twice as much as the total health budget of Vietnam, highlighting that a significant proportion of CHB infections in Vietnam are not being treated and the patients are bearing the extra cost out-of-pocket, or seeking treatment from traditional medicines. CONCLUSIONS: This study confirms that chronic HBV infection poses an unbearable financial burden for the average patient with a GDP per capita of around $1024, and the lack of access to treatment is a social issue in Vietnam. To reduce the number of infected subjects, more health-care investment to improve access and provision of affordable medications by re-examining pharmaceutical policies to attain equity in proper treatment for patients with CHB infections would be needed.
and students (18.3%). The majority (83.2%) were treated with podophyllin paints. At 6 months, 55.0% were cured, 25.2% still had ongoing genital warts, 5.7% had a recurrence, 12.2% were lost to follow-up and 1.5% was discontinued. The median direct medical costs were $998 (range 130–4060) Thai Baht. All patients were treated as out-patients and 71.7% came to hospital without work absenteeism. After having genital warts lesion, work productivity was reduced to 83.0% (17.3) and daily activity was also declined to 82.4% (14.4) from baseline. CONCLUSIONS: Anogenital warts are common STI and tend to be recalcitrant to treatment. They also lead to the reduction on work productivity and daily activity.

PUBLIC HEALTH AND ECONOMIC IMPACT OF ROTAVIRUS VACCINATION PROGRAMS IN KOREA

Lee SE, Chang DP

OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of the three-dose pentavalent rotavirus vaccine in Korea. METHODS: A Markov cohort simulation model was developed to project the expected clinical burden of rotavirus gastroenteritis and the potential impact of universal vaccination (vs. no vaccination) of all children are vaccinated. The break even point of vaccination was estimated to be between KW 50,454, and 61,667 per case. CONCLUSIONS: Implementing a three-dose universal rotavirus vaccination strategy would likely result in a substantial reduction in rotavirus related health-care resource utilization in Korea. These results may be useful for evaluating rotavirus vaccination programs in Korea.

COST-EFFECTIVENESS ANALYSIS OF 1-YEAR PEGINTERFERON ALFA-2A VERSUS 3 YEARS ENTECAVIR FOR THE TREATMENT OF HBEAG-POSITIVE CHRONIC HEPATITIS B IN CHINA

Chai W

OBJECTIVES: The objective of the study was to evaluate the cost-effectiveness of 1-year peginterferon alfa-2a compared to 3 years entecavir for the treatment of HBeAg-positive chronic hepatitis B in China. METHODS: A Markov health-state decision analytical model modifed from the recent PREVENT (PREvent) Model (RTI Health Solution) was used for the analysis of the outcomes for the 3-year-entecavir and HBeAg-positive chronic hepatitis B in China. The model included 10 health states—Chronic hepatitis B (CHB), HBeAg seroconversion, HBsAg loss, CHB with resistance, Decompensated cirrhosis, Hepatocellular carcinoma, Liver transplant, Post-liver transplant and death. The model incorporates a maximum analysis time horizon of 30 years with yearly cycles. The clinical and quality of life data were obtained from published literature and re-confirmed based on a questionnaire survey from a clinical expert panel of 20 hepatitis B specialists. From the perspective of China’s health insurance system, cost data was calculated based on the published literature about economic burden of chronic hepatitis B. A discounting rate at 3% was used to discount medical costs happened at different years. A univariate sensitivity analysis was performed to understand the key drivers and general sensitivity of the model. RESULTS: The model results showed that the utilization of 1-year peginterferon alfa-2a treatment for HBeAg-positive CHB can prolong 0.885 QALYs, compared to the 3 years entecavir treatment. The total cost per patient treated with peginterferon alfa-2a was CNY 151,770 (US$ 22,221), and CNY 129,239 (US$ 18,922) for patient treated with entecavir. The discounted incremental cost per QALY gained for peginterferon alfa-2a was CNY 25,452 (US$ 3,727). CONCLUSIONS: The results of the model suggest that 1 year peginterferon alfa-2a improves health outcomes in a cost-effective manner compared with 3 years entecavir in the treatment of HBeAg-positive chronic hepatitis B in China.